FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the application of a pharmaceutical composition for local application for the prevention of sexually transmitted viral diseases, which includes an effective quantity of a formula (I) compound. The composition is applied locally into the vagina, anus or oral cavity. In formula (I) R1, R2 and R3 represents hydrogen. The invention also relates to the application of the pharmaceutical composition, made in the form of a vaginal cream, and to the application of a condom, covered with the said pharmaceutical composition.
EFFECT: obtaining the pharmaceutical composition for local application for the prevention of sexually transmitted viral diseases.
16 cl, 6 dwg, 1 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
1,2,5-OXADIAZOLE DERIVATIVES, HAVING ANTI-HIV ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD OF INHIBITING HIV-1 INTEGRASE | 2012 |
|
RU2515413C2 |
METHOD FOR ENHANCING OF TESTOSTERONE AND ANALOGOUS STEROID LEVELS IN FEMALES | 2001 |
|
RU2286787C2 |
SOME CHEMICAL STRUCTURES, COMPOSITIONS AND METHODS | 2009 |
|
RU2513636C2 |
ANTI-CANCER STEROID LACTONES UNSATURATED IN POSITION 7(8) | 2011 |
|
RU2572595C2 |
PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | 2019 |
|
RU2819399C2 |
SOME CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS | 2010 |
|
RU2582676C2 |
CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS | 2010 |
|
RU2746319C2 |
SELECTIVE BUTYRYLCHOLIN ESTERASE INHIBITORS | 2005 |
|
RU2386627C2 |
TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2019 |
|
RU2815647C2 |
OBESITY TREATMENT | 2019 |
|
RU2822679C2 |
Authors
Dates
2015-08-20—Published
2010-12-01—Filed